Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

L.A. McKeown

December 12, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

News Daily News

JACC Statement Focuses on PAD Disparities, Gaps in Care

L.A. McKeown

December 04, 2023

News Daily News

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

L.A. McKeown

July 11, 2023

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

Only Half of Revascularized PAD Patients Receive GDMT

L.A. McKeown

February 14, 2023

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Daily News

Meta-analysis: DES Beneficial But May Not Save Limbs, Improve Survival in PAD Patients

May 03, 2013

News Daily News

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

April 12, 2013

News Daily News

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Caitlin E. Cox

December 09, 2012

Advertisement

As More Peripheral Interventions Go Radial, the AHA Offers Some Insights

Scientific Statement Reviews Current Antithrombotic Options in PAD

FDA Approves Bioresorbable Scaffold for BTK Lesions

JACC Statement Focuses on PAD Disparities, Gaps in Care

FDA: All Restrictions on Paclitaxel Devices for PAD Are Removed

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

Only Half of Revascularized PAD Patients Receive GDMT

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

Meta-analysis: DES Beneficial But May Not Save Limbs, Improve Survival in PAD Patients

Zilver PTX 2-Year Results Published: Superior Safety, Efficacy vs. Angioplasty Sustained

PACIFIER Published: Drug-Eluting Balloon Helps Treat Femoropopliteal Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content